2020 Q2 Form 10-Q Financial Statement
#000156459020038399 Filed on August 07, 2020
Income Statement
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| Revenue | $3.391M | $5.666M |
| YoY Change | -40.15% | 94.37% |
| Cost Of Revenue | $1.480M | $2.330M |
| YoY Change | -36.48% | 33.91% |
| Gross Profit | $1.909M | $3.333M |
| YoY Change | -42.72% | 182.7% |
| Gross Profit Margin | 56.3% | 58.82% |
| Selling, General & Admin | $5.870M | $6.250M |
| YoY Change | -6.08% | 115.52% |
| % of Gross Profit | 307.49% | 187.52% |
| Research & Development | $3.900M | $4.790M |
| YoY Change | -18.58% | 39.65% |
| % of Gross Profit | 204.3% | 143.71% |
| Depreciation & Amortization | $380.0K | $280.0K |
| YoY Change | 35.71% | 64.71% |
| % of Gross Profit | 19.91% | 8.4% |
| Operating Expenses | $9.770M | $11.04M |
| YoY Change | -11.5% | 74.41% |
| Operating Profit | -$7.861M | -$7.705M |
| YoY Change | 2.02% | 49.44% |
| Interest Expense | -$630.0K | -$870.0K |
| YoY Change | -27.59% | 17.57% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $0.00 | -$1.480M |
| YoY Change | -100.0% | 55.63% |
| Pretax Income | -$8.491M | -$9.185M |
| YoY Change | -7.56% | 50.4% |
| Income Tax | $10.00K | $10.00K |
| % Of Pretax Income | ||
| Net Earnings | -$8.497M | -$9.195M |
| YoY Change | -7.59% | 50.37% |
| Net Earnings / Revenue | -250.58% | -162.28% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$0.36 | -$436.0K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 23.33M | 21.09M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $139.4M | $96.20M |
| YoY Change | 44.91% | |
| Cash & Equivalents | $51.15M | $47.24M |
| Short-Term Investments | $88.20M | $49.00M |
| Other Short-Term Assets | $1.900M | $1.600M |
| YoY Change | 18.75% | |
| Inventory | $12.60M | $11.22M |
| Prepaid Expenses | ||
| Receivables | $4.400M | $7.105M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $158.2M | $116.1M |
| YoY Change | 36.22% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $4.400M | $4.375M |
| YoY Change | 0.57% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $500.0K | $6.000K |
| YoY Change | 8233.33% | |
| Total Long-Term Assets | $4.900M | $4.881M |
| YoY Change | 0.39% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $158.2M | $116.1M |
| Total Long-Term Assets | $4.900M | $4.881M |
| Total Assets | $163.1M | $121.0M |
| YoY Change | 34.78% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.700M | $6.662M |
| YoY Change | -44.46% | |
| Accrued Expenses | $8.900M | $8.200M |
| YoY Change | 8.54% | |
| Deferred Revenue | $175.0K | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | |
| YoY Change | ||
| Total Short-Term Liabilities | $13.80M | $15.38M |
| YoY Change | -10.26% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $34.40M | $33.90M |
| YoY Change | 1.47% | |
| Other Long-Term Liabilities | $1.200M | $600.0K |
| YoY Change | 100.0% | |
| Total Long-Term Liabilities | $35.60M | $33.90M |
| YoY Change | 5.01% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $13.80M | $15.38M |
| Total Long-Term Liabilities | $35.60M | $33.90M |
| Total Liabilities | $49.40M | $49.85M |
| YoY Change | -0.91% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $113.8M | $71.16M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $163.1M | $121.0M |
| YoY Change | 34.79% |
Cashflow Statement
| Concept | 2020 Q2 | 2019 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$8.497M | -$9.195M |
| YoY Change | -7.59% | 50.37% |
| Depreciation, Depletion And Amortization | $380.0K | $280.0K |
| YoY Change | 35.71% | 64.71% |
| Cash From Operating Activities | -$8.540M | -$12.16M |
| YoY Change | -29.77% | 62.78% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$120.0K | -$150.0K |
| YoY Change | -20.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$40.60M | -$48.95M |
| YoY Change | -17.06% | -801.29% |
| Cash From Investing Activities | -$40.73M | -$49.10M |
| YoY Change | -17.05% | -803.44% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 75.55M | 96.10M |
| YoY Change | -21.38% | 280.44% |
| NET CHANGE | ||
| Cash From Operating Activities | -8.540M | -12.16M |
| Cash From Investing Activities | -40.73M | -49.10M |
| Cash From Financing Activities | 75.55M | 96.10M |
| Net Change In Cash | 26.28M | 34.84M |
| YoY Change | -24.57% | 40.65% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$8.540M | -$12.16M |
| Capital Expenditures | -$120.0K | -$150.0K |
| Free Cash Flow | -$8.420M | -$12.01M |
| YoY Change | -29.89% | 60.78% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
341000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
144000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2403000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-16070000 | ||
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-192242000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-17349000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-16090000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
745000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-16090000 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.21 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
7277237 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
13000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
30000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
43000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16047000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | ||
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
75000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
197000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
385000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
16000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
213000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8852000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
46683000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
92000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
75042000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
631000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
628000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
5966000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
57000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
34000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6895000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-199038000 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
|
186519000 | |
| CY2019Q2 | tmdx |
Conversion Of Preferred Stock Warrants Into Common Stock Warrants Upon Initial Public Offering
ConversionOfPreferredStockWarrantsIntoCommonStockWarrantsUponInitialPublicOffering
|
1239000 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
91401000 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
6000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
220000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
71161000 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
534000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1016000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
277000 | ||
| tmdx |
Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
|
249000 | ||
| tmdx |
Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
|
231000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
49000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
-24000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
131000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3681000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
3226000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-259000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1442000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
816000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
848000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-130000 | ||
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-623000 | ||
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
174000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16715000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19425000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
397000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
151000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
63637000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
48945000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
36025000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-49096000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
339000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1980000 | ||
| tmdx |
Proceeds From Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Commissions
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissions
|
75670000 | ||
| tmdx |
Proceeds From Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Commissions
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissions
|
97367000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
167000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
10000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
197000 | ||
| tmdx |
Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
|
2249000 | ||
| tmdx |
Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
|
2249000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
75695000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
89000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
31060000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
20592000 | |
| tmdx |
Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
|
78000 | ||
| tmdx |
Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
|
1263000 | ||
| tmdx |
Reclassification Of Warrants To Additional Paid In Capital
ReclassificationOfWarrantsToAdditionalPaidInCapital
|
-1239000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
47000 | ||
| tmdx |
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
|
409000 | ||
| tmdx |
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
|
1381000 | ||
| CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
47242000 | |
| CY2020Q2 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
500000 | |
| CY2019Q2 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
500000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. <font style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. </font>As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities.<font style="Background-color:#FFFFFF;color:#212529;"> </font>Actual results may differ from those estimates or assumptions. </p> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk of Concentrations of Credit, Significant Customers and Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company has not experienced any other-than-temporary losses with respect to its cash, cash equivalents, and marketable securities and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. <font style="Background-color:#FFFFFF;color:#000000;">For the fiscal three and six months ended June 30, 2020, one customer represented 17% and 11% of net revenue, respectively. For the fiscal three and six months ended June 29, 2019, one customer represented 17% and 12% of net revenue, respectively. As of June 30, 2020 and December 28, 2019, no customer accounted for 10% or more of accounts receivable.</font> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships. </p> | ||
| CY2019Q2 | tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
549000 | |
| CY2020Q2 | tmdx |
Research Development And Clinical Trials Expenses
ResearchDevelopmentAndClinicalTrialsExpenses
|
400000 | |
| CY2020Q2 | tmdx |
Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
|
35000000 | |
| CY2019Q4 | tmdx |
Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
|
35000000 | |
| CY2020Q2 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
990000 | |
| CY2019Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1139000 | |
| CY2020Q2 | us-gaap |
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
|
385000 | |
| CY2019Q4 | us-gaap |
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
|
285000 | |
| tmdx |
Convertible Preferred Stock Conversion Ratio
ConvertiblePreferredStockConversionRatio
|
3.5-for-one | ||
| CY2020Q2 | us-gaap |
Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
|
1.00 | |
| CY2019 | us-gaap |
Profit Loss
ProfitLoss
|
-33500000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
139400000 | |
| CY2020Q2 | tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
532000 | |
| tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
1245000 | ||
| tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
1163000 | ||
| tmdx |
Research Development And Clinical Trials Expenses
ResearchDevelopmentAndClinicalTrialsExpenses
|
800000 | ||
| CY2019Q2 | tmdx |
Research Development And Clinical Trials Expenses
ResearchDevelopmentAndClinicalTrialsExpenses
|
300000 | |
| tmdx |
Research Development And Clinical Trials Expenses
ResearchDevelopmentAndClinicalTrialsExpenses
|
500000 | ||
| us-gaap |
Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
|
Payment terms for customer orders, including for each of the Company’s primary performance obligations, are typically 30 days for customers in the United States and 30 to 90 days for customers in non-U.S. markets, and such payments do not include payments that are variable, dependent on specified factors or events. | ||
| CY2020Q2 | tmdx |
Contract Assets
ContractAssets
|
0 | |
| CY2019Q4 | tmdx |
Contract Assets
ContractAssets
|
0 | |
| CY2020Q2 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
2900000 | |
| us-gaap |
Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
|
The Company generally satisfies performance obligations within one year of the contract inception date. | ||
| CY2020Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3923000 | |
| CY2019Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
6215000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
12166000 | ||
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
11505000 | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2020Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
88105000 | |
| CY2020Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
119000 | |
| CY2020Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
| CY2020Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
88223000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
60542000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
56000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
60596000 | |
| CY2020Q2 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
124929000 | |
| CY2019Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
72356000 | |
| CY2020Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
6583000 | |
| CY2019Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
4881000 | |
| CY2020Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
959000 | |
| CY2019Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
903000 | |
| CY2020Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
5013000 | |
| CY2019Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
5432000 | |
| CY2020Q2 | tmdx |
Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
|
3702000 | |
| CY2019Q4 | tmdx |
Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
|
3144000 | |
| CY2020Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3441000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3604000 | |
| CY2020Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1715000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1584000 | |
| CY2020Q2 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35000000 | |
| CY2019Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35000000 | |
| CY2020Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | |
| tmdx |
Balloon Payment To Be Paid Percentage
BalloonPaymentToBePaidPercentage
|
0.030 | ||
| CY2020Q2 | us-gaap |
Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
|
0.100 | |
| CY2020Q2 | us-gaap |
Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
|
0.117 | |
| us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
one vote | ||
| us-gaap |
Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
|
0 | ||
| us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
0 | ||
| CY2019Q2 | tmdx |
Preferred Stock Warrants Shares Issued Upon Conversion
PreferredStockWarrantsSharesIssuedUponConversion
|
64440 | |
| CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
631000 | |
| CY2019Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
220000 | |
| CY2020Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
7000000 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y10M24D | ||
| CY2020Q2 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
500000 | |
| CY2019Q2 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
300000 | |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1000000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
600000 | ||
| CY2020Q2 | tmdx |
Tenant Improvements Allowance Receivable
TenantImprovementsAllowanceReceivable
|
200000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
646000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1900000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
1948000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1997000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
2047000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
6452000 | |
| CY2020Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
14990000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2328665 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2081605 | ||
| CY2020Q2 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
4404000 | |
| CY2019Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
4792000 |
